AlphAIAlphAI — Financial news for AI agents
investing.comOCT 282 min read$GSK

FTSE 100 today: Stocks slip ahead of budget; GSK, Unilever results weigh

The FTSE 100 fell 0.30% as investors awaited the UK budget and reacted to earnings from GSK and Unilever. GSK dropped 4.3% despite beating Q3 expectations, while Unilever fell 3.38% after raising its volume growth forecast. The UK finance minister announced the scrapping of gas standing charges. Brent and WTI oil prices rose, while gold prices declined.

Original reporting
investing.com
Published Oct 28, 2026, 8:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GSK
Bearish
high confidence
Mentioned
$GSK · $UL
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GSKBearishMed
01

Why it matters

Earnings beats failed to lift the stocks, suggesting market focus on macro‑policy risk and sector sentiment.

02

Market read

Both stocks moved opposite to their earnings results, indicating short‑term trading opportunities and broader defensive‑sector pressure.

03

What to watch

Budget uncertainty and broader macro‑economic concerns may be driving the weakness more than company fundamentals.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article covers UK market moves ahead of the UK budget, highlighting earnings from GSK and Unilever and their unexpected price declines.

Company-level read

Ticker impact

$GSKBearishHigh confidence
Context

GSK reported Q3 earnings that beat expectations but the share price fell 4.3% on the news.

Expected impact

likely further downside as investors weigh the miss in market reaction despite the beat

Evidence & confidence

The stock already dropped on the day of the earnings release; momentum suggests continued selling pressure.

$ULBearishHigh confidence
Context

Unilever posted stronger sales and raised its volume growth forecast, yet the share price slid 3.38% on the results.

Expected impact

potential further decline as investors digest the mixed reaction to the earnings beat

Evidence & confidence

The immediate price drop indicates the market is not rewarding the earnings beat, suggesting continued weakness.

Market effects

Sector

Both consumer staples giants underperformed, hinting at sector‑wide pressure despite earnings beats.

Regional

UK market weighed down as FTSE 100 slipped 0.30% ahead of the budget.

Global

The mixed reaction to major consumer‑goods earnings may influence global defensive‑stock sentiment.

Counterpoint

What could challenge this read

The earnings beats could be a buying opportunity if the sell‑off is purely sentiment‑driven.

Key entities

  • company
    GSK

    British pharmaceutical giant

  • company
    Unilever

    Consumer‑goods multinational

Read at source← All news

Related articles

OCT 28
$GSKHighAI 8/10

Vaccines worries hit GSK

GSK PLC reported Q3 sales of £8.9B, beating expectations, with core EPS of 54.6p. Shares fell 4% due to weaker vaccine sales and a cautious profit outlook. GSK reaffirmed 2026 guidance but expects EPS growth in the lower half of its 7%-9% range. Jefferies rates GSK 'buy' with a 2,500p target.

finance.yahoo.com2 min
OCT 28
$ULHighAI 8/10

Unilever raises 2026 outlook as third-quarter turnover up 6.7%

Unilever reported a 6.7% rise in third-quarter turnover to €13.271 billion, with underlying sales growth of 5.2%. The company raised its full-year outlook, now expecting underlying volume growth of at least 3%. Beauty & Wellbeing, Personal Care, and Home Care segments showed strong growth, while Foods segment saw minimal growth. The board declared a 3% higher interim dividend. Shares closed down 0.62% on Tuesday.

finance.yahoo.com2 min
OCT 28
$ULMed

Why is Unilever stock sliding today?

Unilever (ULVR) shares fell 3.0% to 4,744.5p after Q3 2026 results showed 5.2% sales growth, beating estimates but missing investor expectations due to volume deceleration. Turnover rose 6.7% to €13.3B. The Wellbeing division declined, and Foods saw minimal growth. UBS cut its target, while Bernstein maintained a Buy rating. The stock traded near session lows, down from 4,892.5p. The FTSE 100 was set to open lower.

investing.com2 min
OCT 28
$GSKHighAI 8/10

Why is GSK stock sliding today?

GSK plc's stock fell 4.6% after its Q3 2026 earnings report, despite beating EPS and sales estimates. Vaccine revenues declined, and operating profit dropped 16%. The company expects lower core EPS growth for the year. Barclays maintained a Sell rating, and the FTSE 100's decline added to the pressure, pushing GSK shares to an intraday low of 1823p.

investing.com2 min
OCT 28
$GSKHighAI 9/10

Key facts: GSK Q3 sales £8.89bn; £2bn buyback; H1 oncology £1.08bn

GSK reported Q3 2026 sales of £8.89bn (+5% CER), core EPS of 54.6p (+1%), and reaffirmed FY guidance. The company completed a £2bn buyback in Q2, with net debt at £20.74bn. Oncology revenue reached £1.08bn in H1. GSK plans to increase late-stage oncology trials and has tariff relief agreements in place. Key drugs showed positive clinical results.

tradingview.com1 min
OCT 28
$GSKHighAI 8/10

GSK Q3 Profit Falls on £328m Charge

GSK reported a 16% drop in Q3 operating profit due to a £328m restructuring charge, despite 5% sales growth. Core profit rose 5%. Specialty Medicines led growth, while vaccines declined. The company reaffirmed 2026 guidance and increased its dividend. Net debt rose to £20.7bn.

asktraders.com2 min